ES2152272T3 - Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica. - Google Patents

Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.

Info

Publication number
ES2152272T3
ES2152272T3 ES94107051T ES94107051T ES2152272T3 ES 2152272 T3 ES2152272 T3 ES 2152272T3 ES 94107051 T ES94107051 T ES 94107051T ES 94107051 T ES94107051 T ES 94107051T ES 2152272 T3 ES2152272 T3 ES 2152272T3
Authority
ES
Spain
Prior art keywords
diabetic
nefropatia
treatment
sulodexide
sulodoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94107051T
Other languages
English (en)
Inventor
Egidio Marchi
Gianfranco Tamagnone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Application granted granted Critical
Publication of ES2152272T3 publication Critical patent/ES2152272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL USO DE SULODOXIDO, UN GLUCOSAMINOGLUCANO DE ORIGEN NATURAL EXTRAIDO DE MUCOSA INTESTINAL DE MAMIFERO, Y DE MEDICINAS QUE LO CONTIENEN EN EL TRATAMIENTO DE PACIENTES QUE SUFREN DE NEFROPATIA DE ORIGEN DIABETICO CONSTITUYE EL OBJETO DE LA PRESENTE INVENCION. LA EFECTIVIDAD DE SULODOXIDO SE HA DEMOSTRADO POR EL DECRECIMIENTO SIGNIFICATIVO DE ALBUMINURIA EN PACIENTES DIABETICOS DE MICROALBUMINURIA Y MACROALBUMINURIA TRATADA CON COMPOSICIONES FARMACEUTICAS ADMINISTRADAS POR RUTA ORAL O INTRAMUSCULAR QUE CONTIENEN CANTIDADES TERAPEUTICAMENTE EFECTIVAS DE DROGA.
ES94107051T 1993-05-10 1994-05-05 Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica. Expired - Lifetime ES2152272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO930205A IT1270846B (it) 1993-05-10 1993-05-10 Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.

Publications (1)

Publication Number Publication Date
ES2152272T3 true ES2152272T3 (es) 2001-02-01

Family

ID=11339016

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94107051T Expired - Lifetime ES2152272T3 (es) 1993-05-10 1994-05-05 Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.

Country Status (12)

Country Link
US (1) US5496807A (es)
EP (1) EP0624374B1 (es)
JP (1) JP2702400B2 (es)
KR (1) KR0165567B1 (es)
AT (1) ATE198278T1 (es)
CA (1) CA2120062C (es)
DE (1) DE69426471T2 (es)
DK (1) DK0624374T3 (es)
ES (1) ES2152272T3 (es)
GR (1) GR3035231T3 (es)
IT (1) IT1270846B (es)
PT (1) PT624374E (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
IT1299969B1 (it) * 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
MXPA03011514A (es) * 2001-06-12 2004-10-28 Keryx Biopharmaceuticals Inc Metodos que utilizan glucosaminoglicanos para tratamiento de nefropatia.
AU2005292202A1 (en) * 2004-10-01 2006-04-13 Keryx Biopharmaceuticals, Inc. Methods using glycosaminoglycans for the treatment of kidney disease
WO2006082643A1 (ja) 2005-02-03 2006-08-10 Taiyo Kagaku Co., Ltd. 糖尿病および／または糖尿病性腎症の予防、改善、または治療用組成物
JP2008540448A (ja) * 2005-05-05 2008-11-20 ケリク ビオファルマセウチカルス インコーポレーテッド 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
CN101522194B (zh) * 2006-08-04 2011-06-15 味之素株式会社 肾功能障碍预防/治疗剂
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
WO2008078176A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
ES2664816T3 (es) 2010-10-27 2018-04-23 Prometic Pharma Smt Limited Compuestos de carboxilato de fenilcetona y usos farmacéuticos de los mismos
EP3833332A4 (en) 2018-07-13 2022-04-20 University of Miami METHODS OF TREATMENT OF KIDNEY DISEASE
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.

Also Published As

Publication number Publication date
EP0624374A1 (en) 1994-11-17
ITBO930205A0 (it) 1993-05-10
CA2120062C (en) 1999-05-25
US5496807A (en) 1996-03-05
CA2120062A1 (en) 1994-11-11
PT624374E (pt) 2001-04-30
IT1270846B (it) 1997-05-13
JP2702400B2 (ja) 1998-01-21
DK0624374T3 (da) 2001-01-29
DE69426471D1 (de) 2001-02-01
EP0624374B1 (en) 2000-12-27
KR0165567B1 (ko) 1999-01-15
DE69426471T2 (de) 2001-05-03
GR3035231T3 (en) 2001-04-30
ITBO930205A1 (it) 1994-11-10
JPH06329541A (ja) 1994-11-29
ATE198278T1 (de) 2001-01-15

Similar Documents

Publication Publication Date Title
ES2152272T3 (es) Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
BR9407720A (pt) Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
ES2174928T3 (es) Metodo para incrementar la diodisponibilidad de composiciones farmaceuticas orales.
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
ES2086644T5 (es) Preparado anovulatorio para la contracepcion hormonal.
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2093440T3 (es) Derivados en la serie de la vitamina d con modificaciones en la posicion 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la preparacion de medicamentos.
ATE506284T1 (de) Blister-karte für pharmazeutische behandlung
ES2188582T3 (es) El uso de ranitidina-citrato de bismuto en combinacion con claritromicina o claritromicina y tetraciclina en la fabricacion de un medicamento para tratar trastornos gastrointestinales.
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
ES2093779T3 (es) Formulacion farmaceutica que contiene diritromicina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624374

Country of ref document: ES